UCB moved quickly into epilepsy-focused cell therapy dealmaking by acquiring Neurona Therapeutics for up to $1.15 billion. The Belgian pharma’s purchase adds Neurona’s NRTX-1001, an epilepsy lead asset, and further intensifies a wave of large neuro-focused transactions in 2026. The structure includes $650 million up front with additional milestone payments, extending a pattern where biopharma buyers scale pipelines through acquisitions rather than building early-stage programs internally. The deal also adds another datapoint to the broader late-cycle valuation environment around neurological disease assets, including those backed by clinical or regulatory catalysts. For investors and partners, the Neurona deal signals that UCB and peers are willing to pay for late-stage differentiation even as deal terms continue to feature milestone risk allocation. The coming quarterly updates will likely focus on how NRTX-1001 advances and how UCB integrates the new platform into its neurology pipeline.